Trial NCT02926638

View at ClinicalTrials.gov 
Org. Study IDs: S1400E
Secondary IDs: NCI-2014-01382 S1400E U10CA180888

Last trial update was posted on 2020-03-19

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Erlotinib Hydrochloride Immunoglobulins Rilotumumab

MeSH Conditions

Carcinoma Lung Neoplasms

Other Conditions

MET Positive Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7

Stopping Reasons

Drug company decided to terminate all sponsored clinical studies involving rilotumumab.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID